2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

European Heart Journal, Journal Year: 2017, Volume and Issue: 39(2), P. 119 - 177

Published: Aug. 26, 2017

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force European Society Cardiology (ESC)

Language: Английский

---

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation, Journal Year: 2019, Volume and Issue: 140(11)

Published: March 17, 2019

Language: Английский

---

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

European Heart Journal, Journal Year: 2017, Volume and Issue: 38(32), P. 2459 - 2472

Published: March 9, 2017

To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD).We assessed whether association between LDL ASCVD fulfils criteria for causality by evaluating totality of from studies, prospective epidemiologic cohort Mendelian randomization randomized trials LDL-lowering therapies. In plasma burden is usually estimated determination cholesterol level (LDL-C). Rare mutations reduced receptor function lead to markedly higher LDL-C a dose-dependent increase in risk ASCVD, whereas rare variants leading lower are associated with correspondingly ASCVD. Separate meta-analyses over 200 including more than 2 million participants 20 person-years follow-up 150 000 events demonstrate remarkably consistent log-linear absolute magnitude exposure vasculature ASCVD; this effect appears increasing duration LDL-C. Both naturally studies intervention consistently any mechanism lowering particle concentration should reduce proportional reduction cumulative LDL-C, provided achieved concordant number there no competing deleterious off-target effects.Consistent numerous multiple different types unequivocally establishes causes

Language: Английский

---

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Journal of the American College of Cardiology, Journal Year: 2019, Volume and Issue: 74(10), P. e177 - e232

Published: March 18, 2019

Language: Английский

---

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

New England Journal of Medicine, Journal Year: 2020, Volume and Issue: 382(16), P. 1507 - 1519

Published: March 18, 2020

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing.We enrolled patients atherosclerotic cardiovascular disease (ORION-10 trial) and or an risk equivalent (ORION-11 who had elevated LDL despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned a 1:1 ratio to receive either (284 mg) placebo, administered by subcutaneous injection on day 1, 90, every 6 months thereafter over period 540 days. The coprimary end points each trial placebo-corrected percentage change level from baseline 510 time-adjusted after 90 up 540.A total 1561 1617 underwent randomization ORION-10 ORION-11 trials, respectively. Mean (±SD) 104.7±38.3 mg per deciliter (2.71±0.99 mmol liter) 105.5±39.1 (2.73±1.01 liter), At 510, reduced 52.3% (95% confidence interval [CI], 48.8 55.7) 49.9% CI, 46.6 53.1) trial, corresponding 53.8% 51.3 56.2) 49.2% 46.8 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events generally similar placebo groups although injection-site adverse more frequent than (2.6% 0.9% 4.7% 0.5% trial); such reactions mild, none severe persistent.Reductions approximately 50% obtained inclisiran, subcutaneously months. More occurred placebo. (Funded Medicines Company; ClinicalTrials.gov numbers, NCT03399370 NCT03400800.).

Language: Английский

---

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

European Heart Journal, Journal Year: 2020, Volume and Issue: 41(24), P. 2313 - 2330

Published: Jan. 8, 2020

Abstract

Language: Английский

---

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Journal of Atherosclerosis and Thrombosis, Journal Year: 2018, Volume and Issue: 25(9), P. 846 - 984

Published: Aug. 21, 2018

Revisions 1. CQs and Systematic Review (SR)In the subsections on dyslipidemia in assessment of risk factors, absolute ASCVD, lipid management targets as well drug therapy diet improving lifestyle habits, we created performed an SR based MINDS method.For our SR, essentially chose literature published before end 2015. Calculation Absolute RiskFollowing 2012 version, has been using calculation described this set guidelines.The NIPPON DATA80, which was used to calculate result baseline surveys conducted when statins were not available.It is suited observation natural course disease, data are highly useful; however, death instead disease onset outcome absence information LDL-C HDL-C major issues, addition some others.SR indicated that Suita study, CAD its outcome, most suitable for guidelines.We believe determination incidence rate overall enabled a clearer demonstration importance each risk.Classification Evidence Levels Epidemiological Studies E-Ia: Meta-analysis cohort studies E-Ib: Cohort E-II: Case-control cross-sectional E-III: Descriptive (case series) Recommendation A Strong recommendation B Weak Recommendations made according consensus by word "consensus.

Language: Английский

---

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

The Lancet, Journal Year: 2019, Volume and Issue: 393(10170), P. 407 - 415

Published: Feb. 1, 2019

Statin therapy has been shown to reduce major vascular events and mortality in a wide range of individuals, but there is uncertainty about its efficacy safety among older people. We undertook meta-analysis data from all large statin trials compare the effects at different ages.

Language: Английский

---

The 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS)

European Journal of Vascular and Endovascular Surgery, Journal Year: 2018, Volume and Issue: 55(3), P. 301 - 302

Published: March 1, 2018

Language: Английский

---

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks

JAMA Cardiology, Journal Year: 2018, Volume and Issue: 3(3), P. 225 - 225

Published: Jan. 31, 2018

Current guidelines advocate the use of marine-derived omega-3 fatty acids supplements for prevention coronary heart disease and major vascular events in people with prior disease, but large trials have produced conflicting results.

Language: Английский

---